Cargando…
Optimal Antithrombotic Treatment of Patients with Atrial Fibrillation Early after an Acute Coronary Syndrome—Triple Therapy, Dual Antithrombotic Therapy with an Anticoagulant… Or, Rather, Temporary Dual Antiplatelet Therapy?
The combination of atrial fibrillation (AF) and acute coronary syndrome (ACS) is a complex situation in which a three-dimensional risk—cardioembolic, coronary, and hemorrhagic—has to be carefully managed. Triple antithrombotic therapy (TAT) is burdened with a high risk of serious bleeding, while dua...
Autores principales: | Limbruno, Ugo, De Sensi, Francesco, Cresti, Alberto, Picchi, Andrea, Lena, Fabio, De Caterina, Raffaele |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7464261/ https://www.ncbi.nlm.nih.gov/pubmed/32824861 http://dx.doi.org/10.3390/jcm9082673 |
Ejemplares similares
-
Optimizing antiplatelet / antithrombotic therapy
por: Srijithesh, P. R.
Publicado: (2010) -
Comparison of Systematic Ticagrelor-Based Dual Antiplatelet Therapy to Selective Triple Antithrombotic Therapy for Left Ventricle Dysfunction Following Anterior STEMI
por: Bastiany, Alexandra, et al.
Publicado: (2018) -
Comparison of early clinical outcomes between dual antiplatelet therapy and triple antithrombotic therapy in patients with atrial fibrillation undergoing percutaneous coronary intervention
por: Park, Jiesuck, et al.
Publicado: (2022) -
Dual antiplatelet therapy with concomitant anticoagulation: current perspectives on triple therapy
por: Patail, Haris, et al.
Publicado: (2023) -
Optimization of antiplatelet/antithrombotic therapy for secondary stroke prevention
por: Srivastava, Padma
Publicado: (2010)